Research programme - small molecule therapeutics - Adlai Nortye

Drug Profile

Research programme - small molecule therapeutics - Adlai Nortye

Alternative Names: AN 1015; AN 2015; AN 3005; AN 4005; IDO inhibitor - Adlai Nortye; Indoleamine-pyrrole- 2,3-dioxygenase inhibitor - Adlai Nortye

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adlai Nortye
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Acute myeloid leukaemia; Breast cancer; Head and neck cancer; Malignant melanoma; Mantle-cell lymphoma; Myelodysplastic syndromes; Non-small cell lung cancer

Most Recent Events

  • 28 Nov 2017 Early research in Acute myeloid leukaemia in China (unspecified route)
  • 28 Nov 2017 Early research in Breast cancer in China (unspecified route)
  • 28 Nov 2017 Early research in Head and neck cancer in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top